Tempus AI, Inc. has entered into a collaboration with Median Technologies to integrate Median’s lung cancer screening solution, eyonis LCS, into the Tempus Pixel platform. Tempus is widely recognized for advancing precision medicine through artificial intelligence, and this partnership is aimed at strengthening clinical decision making in lung cancer detection and management. By incorporating Median’s technology into Pixel, Tempus is expanding the tools available to radiologists and care teams who rely on imaging data to guide diagnosis and treatment planning.
Health Technology Insights: Corus Orthodontists Secures C$20 Million Equity Investment
Lung cancer screening rates remain lower than recommended levels across the United States. Research from the American Cancer Society indicates that only a fraction of eligible individuals underwent screening in 2024. Increasing participation among high risk populations could prevent tens of thousands of deaths within a five year period. Median’s eyonis LCS is designed to address this gap by using artificial intelligence to assist in both detecting lung nodules and evaluating their likelihood of malignancy from a single CT scan. The software recently received 510 k clearance from the U.S. Food and Drug Administration, marking an important regulatory milestone.
Health Technology Insights: AACN Teams with Xapify to Digitize Competence Framework
With this agreement, Tempus will embed eyonis LCS into Tempus Pixel, an FDA cleared and CE marked platform that delivers advanced imaging analytics and structured reporting. The addition of Median’s technology will allow clinicians to assess and score lung nodules at the point of detection, helping teams prioritize patients based on risk. This capability supports more informed triage decisions within lung cancer screening programs and may improve early stage identification.
Fredrik Brag, CEO and Founder of Median Technologies, said the collaboration with Tempus represents an important step toward making eyonis LCS broadly accessible to patients across the country. He noted that Tempus brings strong expertise in AI driven precision medicine along with a robust data and technology infrastructure, making it well positioned to support widespread adoption.
Razik Yousfi, SVP and General Manager of AI Products at Tempus, stated that artificial intelligence delivers the greatest impact when it enables earlier and more accurate disease detection. He explained that expanding the Pixel platform with advanced lung screening capabilities is intended to help radiologists manage growing workloads while focusing on early diagnosis. Yousfi added that the collaboration is centered on improving care standards and expanding access to effective screening tools.
Tempus has continued to build out its diagnostic portfolio in recent years. The company previously acquired Arterys, bringing AI imaging applications for lung, cardiac, and other radiology use cases into its ecosystem. It later acquired Paige, gaining access to a large collection of annotated pathology slides to further strengthen its data foundation. Together, these investments and collaborations reflect Tempus’ ongoing effort to enhance precision medicine through integrated artificial intelligence solutions.
Health Technology Insights: SEQSTER Expands Partnership with Praxis Precision Medicines
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
